Jane Street Group LLC Has $235,000 Stock Position in CureVac (NASDAQ:CVAC)

Jane Street Group LLC lifted its holdings in shares of CureVac (NASDAQ:CVAC) by 239.0% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 79,247 shares of the company’s stock after buying an additional 55,867 shares during the period. Jane Street Group LLC’s holdings in CureVac were worth $235,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of CVAC. Bank of New York Mellon Corp acquired a new position in shares of CureVac during the 2nd quarter worth $54,000. Vanguard Personalized Indexing Management LLC grew its position in CureVac by 99.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 44,044 shares of the company’s stock worth $147,000 after acquiring an additional 21,999 shares during the last quarter. XTX Topco Ltd bought a new stake in CureVac during the 2nd quarter worth $108,000. Point72 Asset Management L.P. bought a new stake in CureVac during the 2nd quarter worth $8,237,000. Finally, Green Alpha Advisors LLC grew its position in CureVac by 41.3% during the 3rd quarter. Green Alpha Advisors LLC now owns 27,319 shares of the company’s stock worth $80,000 after acquiring an additional 7,979 shares during the last quarter. Institutional investors and hedge funds own 17.26% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, JMP Securities restated a “market outperform” rating and set a $16.00 price objective on shares of CureVac in a research report on Monday, September 16th.

CureVac Trading Down 0.5 %

Shares of CVAC stock opened at $4.21 on Friday. The firm has a market capitalization of $942.53 million, a P/E ratio of 7.65, a P/E/G ratio of 0.24 and a beta of 2.50. CureVac has a twelve month low of $2.21 and a twelve month high of $5.28. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The stock’s fifty day simple moving average is $3.09 and its 200 day simple moving average is $3.15.

CureVac Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.